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Studies on the Synthesis, Stability and Conformation 
of 2-Sulfonyl-Oxetane Fragments 
K. F. Morgan,a I. A. Hollingsworthb and J. A. Bulla* 
2-(Arylsulfonyl)oxetanes have been prepared as new structural motifs of interest for medicinal 
chemistry. These are designed to fit within fragment space and be suitable for screening in 
fragment based drug discovery, as well as being suitable for further elaboration or 
incorporation into drug-like compounds. The oxetane ring is constructed through an efficient 
C–C bond forming cyclisation which allows the incorporation of a wide range of aryl-sulfonyl 
groups. Furthermore, biaryl-containing compounds can be accessed through Suzuki-Miyaura 
coupling from halogenated derivatives. With a number of oxetane containing fragment 
compounds available, their pH stability was assessed, indicating good half-life values for 
mono-substituted aryl sulfonyl oxetanes across the pH range (1 to 10). Solubility and 
metabolic stability data is also reported. Finally, the conformation of the fragments is assessed 
computationally, providing an indication of possible binding orientations.  
 
Introduction 
Recent years have seen significant interest in the preparation of 
new chemical motifs for medicinal chemistry.1 New motifs, 
including scaffolds and isosteres, can access new areas of 
chemical space and confer improved physicochemical 
properties, as well as intellectual property advantages when 
incorporated into target molecules.2 We are interested in new 
chemical motifs for incorporation into drug-like compounds, 
which themselves also provide interesting fragments for 
fragment based drug discovery (FBDD), to be screened in their 
own right.  
 FBDD has become a well-established and important 
approach to the development of new drugs and lead 
compounds.3 An important advantage of fragment screening is 
the improved coverage of available chemical space offered by 
screening smaller molecules.4,5 The small size of fragments 
means that hits are likely to provide desirable starting points for 
a medicinal chemistry programme, to allow increases in MW 
and lipophilicity during optimisation of compound properties.6,7 
To maximise coverage of chemical space, library design will 
consider many parameters. Within these, the Astex guidelines 
for fragments are often adhered to (Rule-of-3: MW <300, clogP 
≤3, number of H-bond donors/acceptors ≤3),8 though increased 
numbers of H-bond acceptors can aid solubility and provide 
additional binding elements.9 Recent literature has called for an 
increase in the proportion of sp3 rich fragments and their 
reduction in planarity.10 This is because of observations that 
more sp3-rich molecules and aliphatic heterocycles can offer 
improved levels of success through development, relative to 
highly aromatic compounds.11,12 In addition, more sp3 rich 
fragments may offer the potential for an improved hit rate in 
challenging biological targets such as protein-protein 
interactions (PPI).13,4 Although there remains debate over the 
advantages of “3-D fragments”, there is significant interest to 
develop synthetic methods towards novel small non-planar 
fragments that access new chemical space.2,4,7  
 In this context, we considered that novel substituted 
oxetanes could provide interesting chemical motifs and 
fragments.14,15 The oxetane motif is found in a variety of 
natural products and biologically active compounds (Figure 
1A).16 However, the recent increased interest in applying 
oxetanes in medicinal chemistry follows studies by Carreira and 
co-workers, in which the incorporation of 3,3-disubstituted 
oxetanes in place of gem-dimethyl groups was studied (Figure 
1B).17  
 
Figure	  1.	  The	  oxetane	  motif	  in	  natural	  products	  and	  as	  bioisosteres	  in	  medicinal	  
chemistry.	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 It was demonstrated that this use of oxetanes as replacement 
groups could impart improved physicochemical properties to 
drug-like compounds, without a significant increase in 
molecular weight.18a Carreira extended this approach to use 
oxetanes as replacements for carbonyl groups,18,1d with the 
oxetane providing comparable H-bonding properties, and 
recently oxetanes have been introduced in peptide mimics.19 
Similarly, Carreira has subsequently developed several novel 
spirocyclic systems containing oxetanes, e.g. as replacements 
for a morpholine group (Figure 1B).20 Following these 
advances, the appearance of oxetanes in medicinal chemistry 
has seen a notable increase, with particular aims of improving 
solubility or metabolic stability of drug-like compounds.21,22,23 
 We recently communicated our initial studies into the 
synthesis of a series of novel 2-sulfonyl oxetanes 1a-d, 
designed to possess attractive characteristics as fragments for 
fragment based drug discovery (Figure 2).14  
 
Figure	   2.	   Previously	   reported	   2-­‐aryl	   sulfonyl	   oxetanes	   as	   fragments	   and	   their	  
molecular	  properties	  (Reference	  14)‡	  
 The incorporation of the small and polar oxetane 
heterocycles and the sulfonyl group provides desirable 
molecular weight and lipophilicity properties for fragments, and 
affords potential sites for binding interactions. Furthermore, we 
intended the functionality to facilitate further derivatisation for 
fragment growth or incorporation into larger compounds. Here 
we report our full studies into the synthesis of a wide array of 
2-sulfonyl oxetanes, as well as derivatisation of the initial 
fragments maintaining the intact oxetane ring. We also report 
studies relevant to their potential and properties as fragments, 
indicating their stability to a range of pH conditions as well as 
indications of metabolic stability, solubility and calculated 
conformational features.  
 
Results and Discussion 
Synthesis of 2-(arylsulfonyl)oxetane derivatives 
The synthesis of the oxetane motif remains a challenge due to 
the poor thermodynamics and kinetics of cyclisation to form 4-
membered rings. The most widely used synthetic approaches to 
oxetanes involve C–O bond formation, often via intramolecular 
alkylation of a hydroxyl group, by a number of methods.24,25 
These approaches were not suitable for the proposed sulfonyl 
oxetane compounds due to rapid elimination from the required 
α-hydroxy sulfonyl intermediates. Studies into displacing the 
leaving group adjacent to the sulfonyl group with a primary 
alcohol were similarly unsuccessful. Therefore, a different 
approach was required to access the proposed 2-sulfonyl 
oxetanes, for which we examined a C–C bond forming 
cyclisation approach (Scheme 1).14,15,26 We envisaged that 
deprotonation next to the sulfone would provide a more 
reactive carbanion (vs an oxy-anion) that may facilitate 
cyclisation to the 4-membered ring.  
 
Scheme	  1.	  Carbon-­‐carbon	  bond	  forming	  approach	  to	  2-­‐aryl	  sulfonyl	  oxetanes.	  	  
 To commence the synthesis towards the precursor for 
cyclisation, of general structure 2, we required 
chloromethylsulfides 5a-k (Scheme 2). Chloromethyl phenyl 
sulfide 5a was commercially available and used as supplied. 
Most other examples were prepared by chlorination of the aryl 
methyl sulfide with NCS (1.1 equiv), in either CCl427 or latterly 
with DCE, which was equally efficient. Filtration through 
silica, eluting with CH2Cl2, gave the sulfides in high yield and 
purity without further purification. For pyridyl substrate 5d, the 
chloromethyl sulfide was obtained in one step by alkylation of 
mercaptopyridine 4d with NaH and chloroiodomethane in 
DMF.28 Chloromethyl sulfides 5 were then used to alkylate 
ethylene glycol. Ethylene glycol was employed as a solvent, 
which avoided double alkylation and provided S,O-acetals 6a-
k. Tosylation of the primary alcohol followed by oxidation with 
excess mCPBA to the corresponding sulfones afforded the 
cyclisation precursors 2 in high yields.  
 
Scheme	   2.	   Synthetic	   route	   to	   the	   cyclisation	   precursors;	   sulfone	   2	   from	   the	  
corresponding	   chloromethyl	   sulfides.	   a	   See	   reference	   14	   for	   compounds	   a-­‐d.	  	  
b	  Isolated	  as	  a	  9:1	  mixture	  with	  bis(pyridine-­‐2-­‐ylthio)methane.	  
 Optimisation of the C–C bond forming cyclisation was 
performed on compound 2b.14 Initially sulfone 2b was 
deprotonated with a variety of bases; freshly made LiHMDS 
was optimal. The deprotonation and cyclisation occurred 
efficiently at 0 ºC. The order of addition of reactants was 
important; when LiHMDS was added to a solution of the 
sulfone it gave a marked increase in yield when compared to 
adding sulfone 2b to a solution of LiHMDS. Decreasing the 
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reaction time to 1 h and the equivalents of base to 1.1 afforded 
the optimum cyclisation conditions. Under these conditions, a 
93% isolated yield was obtained on a 6 mmol scale, providing 
>1g of the sulfonyl oxetane fragment 1b (Scheme 3).  
 These conditions (1.1 equiv LiHMDS, 0 ºC, 1 h) were 
applied to sulfones 2a,c-k to afford the resulting 2-sulfonyl 
oxetanes in yields from 46-95% (Scheme 3). The cyclisation 
was successful with a variety of aromatic groups of varying size 
and electronics. A phenyl, para-tolyl, para-chloro phenyl and 
2-pyridine ring were all high yielding under the optimised 
conditions 1a-d. Substitution at the ortho- and meta-positions 
of the aromatic ring were also successful 1e-g. As well as 
chloro substituents, both the fluoro and bromo substrates, 1h 
and 1i, were obtained in high yields (83% and 86%). The 
introduction of halogen substituents at all positions provides 
opportunities for further derivatisation of the sulfonyl oxetane. 
Both electron withdrawing and electron donating substrates 
were successful 1j and 1k. Each of the compounds prepared 
(Scheme 3) fit well into fragment space in terms of molecular 
weight (MW) and lipophilicity values (cLogP). Furthermore 
they present a number of H-bond acceptors, generally <4 as is 
appropriate for additional binding elements and further points 
for derivatisation.9 
  
Scheme	   3.	   Library	   of	   2-­‐sulfonyl	   oxetane	   fragments	   synthesised	   via	   an	  
intramolecular	  C–C	  bond	  forming	  cyclisation.	  
 As new motifs we were interested in methods for the 
incorporation of the 2-sulfonyl oxetanes into larger compounds, 
and as fragments we desired methods for their growth into lead-
like and drug-like compounds were they to be a hit. With this in 
mind, an important aspect of the design of these fragments was 
to allow their further derivatisation. Initially, functionalisation 
on the intact oxetane ring via lithiation followed by 
electrophilic trapping was investigated, to generate 2,2-
disubstituted oxetanes (Scheme 4). This deprotonation and 
electrophilic trapping was achieved under two sets of 
conditions appropriate for different electrophiles, both in 
excellent yields. When LiHMDS was employed the electrophile 
was added immediately. To maintain stability of the lithiated 
intermediate, the reagents were added at –78 ºC then warmed to 
0 ºC for an in situ quench. However when nBuLi was used, to 
achieve full deprotonation the electrophile was added after a 
short deprotonation time and the reactions were maintained at  
–78 ºC. For compounds 8-12, purification on silica afforded 
reduced yields, and compounds required purification on basic 
alumina.29 
 
Scheme	   4.	   Functionalisation	   of	   2-­‐aryl	   sulfonyl	   oxetanes	   directly	   on	   the	   intact	  
oxetane	  ring	  via	  lithiation.14	  
 We were interested in the viability of the 2-sulfonyl oxetane 
units as cross-coupling partners, to access functionalised biaryl 
systems. This was realised through Suzuki-Miyaura cross-
coupling using Pd(OAc)2 with Buchwald’s SPhos ligand 
(Scheme 5).30  
 
Scheme	  5.	  Catalytic	  cross-­‐coupling	  of	  chloro	  and	  bromo-­‐substituted	  aryl	  sulfonyl	  
oxetanes	  accessing	  a	  variety	  of	  biaryl	  products.	  See	  reference	  14	  for	  compounds	  
13-­‐16.	  
 The para-chloro phenyl substrate 1c was successfully 
coupled with a variety of boronic acids, both electron 
withdrawing and electron donating to afford biaryls 13-16.31 
Under these cross-coupling conditions, the halide and boronic 
acid were heated in water/dioxane at 65 ºC in the presence of 
K2CO3; it was interesting to note that no degradation or ring 
opening of the oxetane was observed. The para-bromo phenyl 
sulfonyl oxetane 1i was also coupled with 4-
cyanophenylboronic acid and 4-(hydroxymethyl)-phenyl-
boronic acid in good yields, installing further reactive handles. 
Pleasingly both meta and ortho chlorides 1g and 1f were also 
successfully cross-coupled with 4-methoxyphenyl-boronic acid 
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under the same reaction conditions to afford biaryl compounds 
19 and 20, demonstrating how the 2-sulfonyl oxetane fragments 
could be derivatised in a variety of directions (Scheme 5). 
Studies into the Stability of Sulfonyl Oxetanes 
Having accessed a large variety of 2-sulfonyl-oxetanes we were 
interested to understand more about their desirability as 
fragments, in particular their stability under acidic conditions. 
Initial observations on stability to storage showed that all of the 
oxetane compounds were stable when kept under argon at  
–20 ºC. Oxetanes 1a-d were stored under argon at –20 ºC for 
>12 months and samples of fragments 1b and 1d were also 
stored at room temperature without any additional precautions 
for >3 months with no observable degradation. Similarly, biaryl 
oxetanes 13 and 16 were stable when stored under argon at  
–20 ºC for at least 8 months and at rt for at least 3 months. On 
the other hand, functionalised oxetanes 8 and 9, which are 
alkylated directly on the oxetane ring, underwent an unexpected 
rearrangement when stored at room temperature for more than 
24 hours. While stable at –20 ºC for >2 months without 
degradation, 8 and 9 underwent rearrangement to quantitatively 
afford the corresponding β-sulfonyl ketones 21 and 22 at higher 
temperatures. The proposed mechanism is shown in scheme 6. 
With the increased steric demands of the α-alkylated derivatives 
we hypothesise that the sulfonyl group was lost to afford a 
tertiary carbocationic intermediate, possibly stabilised by the 
adjacent oxygen. Subsequent ring opening by attack of the 
sulfonyl group would afford the observed product. 
Consequently, these 2-alkylated 2-sulfonyl oxetanes were 
excluded from further stability studies and were considered to 
be less viable as fragments. 
 
Scheme	  6.	  Proposed	  decomposition	  pathway	  of	  alkylated	  oxetanes	  8	  and	  9.	  
 A selection of mono-substituted sulfonyl oxetanes was 
subjected to pH stability studies. The solution stability of 
compounds 1a-c, 1h and 1k as well as biaryls 13 and 16 were 
assessed by incubating each compound (10 µM) for  
15 hours at 70 ºC at pH 1, 4, 6, 8 and 10 in buffers containing 
5% v/v 2-methoxyethanol.32 Analysis was performed at regular 
intervals by LC-UV-MS. Half-lives were measured at 70 ºC 
then predicted at 25 ºC calculated using a factor of two for the 
reduction in rate for every 10 degree reduction in temperature 
(generally regarded as a worst case scenario). The extrapolated 
half-lives at 25 ºC are shown in table 1. 
Table 1: Half-lives of selected compounds, showing their stability in acidic 
and basic conditions. 
Entry Compound Extrapolated Half Life (days)a 
 
 
 pH: 
1  
pH: 
4 
pH: 
6 
pH: 
8 
pH: 
10 
1 Ph– 1a 4.0 5.0 5.3 5.3 3.7 
2 Me-C6H4– 1b 7.1 10.2 9.9 9.1 9.2 
3 Cl-C6H4– 1c 1.7 1.9 1.9 1.8 1.8 
4 F-C6H4– 1h 2.0 2.7 2.4 2.2 3.5 
5 MeO-C6H4– 1k 6.3 11.2 11.5 11.1 10.0 
6 Ph-C6H4– 13 3.9 4.7 4.7 4.6 4.6 
7 MeO-C6H4-C6H4– 16 4.6 5.7 5.7 7.1 5.3 
a Half life calculated at 25 ºC, extrapolated from data measured at 70 ºC using 
a two-fold reduction in rate for every 10 degree drop in temperature. 
 For all compounds tested, 1a-c,h,k and 13 and 16, good 
half-lives were observed across the pH range, with each 
compound showing a similar trend. In particular it was notable 
that there was no significant acid sensitivity; decomposition 
pathways could be envisaged under acidic conditions through 
the protonation and ring opening of the oxetane, or through 
protonation of the sulfonyl group and expulsion of aryl sulfinic 
acid (similar to the first step of the proposed rearrangement in 
scheme 6). Despite this possibility, the half-lives at pH 1 were 
comparable to those under neutral conditions in most cases.  
 The fate of the compounds under the assay conditions was 
not conclusive from the MS study. One pathway for 
decomposition was likely to have been hydrolysis to the parent 
sulfonic acid, as indicated in Scheme 7 for the chlorinated-
substrate 1c. This would give rise to a [M-H]– signal, which 
was observed during the mass spectrometry studies.  
 
Scheme	  7.	  One	  possible	  pathway	  for	  decomposition	  during	  the	  stability	  studies.	  	  
 Comparing entries 1, 2 and 5 (table 1), it was apparent that 
the half-lives increased as the aromatic group became more 
electron rich. This would be consistent with a pathway for 
decomposition involving a nucleophilic attack at the sulfur 
center, promoted by the less electron rich/more electron 
withdrawing substituents on the aryl group. It could also be 
related to an increased α-acidity or leaving group ability of the 
more electron withdrawing substituents. This trend was further 
apparent with the biaryl compounds, 13 and 16. In general the 
half-lives were comparable to the phenyl derivative, however 
the more electron rich methoxy-substituted biaryl had a longer 
half-life under all pH conditions, compared to biphenyl 13 
(entries 6 and 7, table 1). 
 The logD7.4 was measured for a small selection of the 
compounds and indicated the hydrophilic nature of these 
fragments. As can be seen from table 2, there is not a good 
correlation with clogP. Additionally, the solubility of 
compounds 1d and 16 was assessed in aqueous phosphate 
buffer at pH 7.4 after 24 hours at 25 ºC, however, given the 
lipophilicity and molecular weight of these fragments, these 
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values were disappointingly low, especially for the pyridyl 
substrate. Further work exploring the possible hydrogen 
bonding and solvation of these fragments would be required to 
fully understand these observations.  
Table 2: Solubility and LogD of sulfonyl oxetanes. 
Entry Compound Measured 
LogD b 
cLogP‡ Solubility 
(µM) a 
1 Pyr 1d –0.3 –1.3 37 
2 4-MeO-C6H4 16 <–1.1 1.3 99 
3 4-F-C6H4 1h <–1.6 0.11 - 
a Determined by LCMSMS following incubation of solid compound in pH 
7.4 phosphate buffer at 25oC. b Distribution coefficient between 1-octanol and 
aqueous phosphate buffer at pH 7.4 at 25oC determined by LCMSMS.  Other 
compounds failed to give an acceptable MSMS response under these assay 
conditions. 
Finally for compound 1d, the intrinsic clearance in rat 
hepatocytes was measured. The value of 2.8 µl/min/1E6 cells 
reflects low turnover as would be expected for a fragment of 
low lipophilicity, and indicates no inherent liability associated 
with the fragment in terms of metabolism.  
Conformational Analysis 
A potentially desirable feature of the 2-sulfonyl oxetanes is the 
presence of few rotatable bonds, with only rotation around the 
oxetane-sulfonyl bond possible. In order to understand more 
about the conformation of these fragments and how they might 
bind to a potential target the conformational profile of the 2-
(phenylsulfonyl)oxetane 1a was investigated by computational 
methods; a DFT relaxed coordinate scan was performed at 
B3LYP/6-31G9(d,p) level of theory with default implicit 
solvation in water (scrf = water).33 The dihedral angle around 
the oxetane C-S bond was varied in 10-degree increments 
between 0 and 360 degrees. The resulting conformational 
profile is shown in figure 3. 
 
 
Figure	  3.	  Results	  of	  the	  conformational	  calculations	  of	  phenyl	  sulfonyl	  oxetane	  1a	  
and	  the	  three	  low	  energy	  conformations.	  
 There are three preferred conformations corresponding to 
the staggered conformation of all bonds; with maxima at the 
eclipsed conformations. Energy minima were observed 
corresponding to dihedral angles of 60, 180 and 300 degrees. 
Representations of the conformations with the lowest energy 
are shown in figure 3. The conformation with a 60 degree 
dihedral angle had the lowest energy presumably due to 
opposing dipoles as well as minimal steric interactions between 
the oxetane and phenyl ring. The barriers to rotation as well as 
the energy difference between the three staggered 
conformations were relatively low (maximum 4 kcalmol-1) so 
the fragment may adopt any of these three conformations.  
 The same process was performed for the 2-pyridyl substrate 
1d. As there were two possible low energy orientations of the 
pyridyl ring, energies were calculated for each of these, (figure 
4). 
 
 
Figure	  4.	  A)	  Results	  of	  the	  conformational	  calculations	  of	  pyridyl	  sulfonyl	  oxetane	  
1d;	   B)	   The	   two	   possible	   orientations	   of	   the	   pyridyl	   ring;	   C)	   Lowest	   energy	  
conformation	  for	  2-(oxetan-2-ylsulfonyl)pyridine 1d	  
 Both orientations of the pyridyl group 1d-A and 1d-B had 
three preferred conformations when altering the dihedral angle 
around the oxetane-C-S bond; similar to those seen for  
2-(phenylsulfonyl)oxetane 1a. The minimal energy 
conformation correlates to the staggered configuration. 
Conformation 1d-A, with a dihedral angle of 60 degrees was 
the lowest energy conformation due to opposing dipoles of the 
pyridine/oxetane, as well as minimal steric hindrance. 
However, the barrier to rotation was again low.  
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 The preferred conformation of 2-(2-
methylbenzenesulfonyl)-oxetane 1e, was also investigated. The 
calculations were performed for both orientations of the methyl 
group. The lowest energy conformation had a dihedral angle of 
60 degrees, which we postulate results from a favourable 
intramolecular Van der Waals interaction between a proton on 
the benzylic CH3 and the oxetane oxygen (figure 5).34 
 
Figure	  5.	  Lowest	  energy	  conformation	  of	  2(2-­‐methylbenzenesulfonyl)oxetane	  1e	  	  
Conclusions 
In summary we have successfully synthesised a wide array of 
novel 2-sulfonyl oxetanes that conform well to fragment 
criteria. These have been further functionalised in a variety of 
directions via lithiation and Suzuki cross-couplings, as would 
be appropriate for fragment hits. We have studied their stability 
and are pleased to show the fragments are stable to basic and 
more pleasingly acidic conditions. However the derivatised 
fragments, alkylated on the oxetane ring, undergo a 
rearrangement at room temperature. Finally calculations have 
been performed to understand the preferred conformations of a 
range of these fragments. These understandings enhance the 
desirability of 2-sulfonyl oxetanes as new motifs for 
incorporation into medicinal chemistry programs or for use as 
fragments in FBDD. 
 
Acknowledgements 
For financial support we gratefully acknowledge the EPSRC 
(Career Acceleration Fellowship to J.A.B., EP/J001538/1, and 
Impact Acceleration Account, EP/K503733/1), Imperial 
College London, and AstraZeneca (CASE-type funding). Thank 
you to Philip MacFaul (AstraZeneca) for performing the 
stability studies. Thank you to Tom Taylor for early synthetic 
investigation, and to Prof Alan Armstrong for generous support. 
We acknowledge the Imperial College High Performance 
Computing Service (http://www.imperial.ac.uk/ict/services/ 
teachingandresearchservices/highperformancecomputing), and 
the EPSRC National Mass Spectrometry Facility, Swansea.  
 
Notes and references 
a Department of Chemistry Imperial College London, South Kensington, 
London SW7 2AZ, UK. Tel: +44 (0)20 7594 5811. E-mail: 
j.bull@imperial.ac.uk. 
b AstraZeneca Mereside, Alderley Park, Cheshire, SK10 4TG, UK. 
† Electronic Supplementary Information (ESI) available: experimental, 
characterization data and NMR spectra (1H and 13C) for all novel 
compounds. See DOI: 10.1039/b000000x/ 
‡ cLogP values were determined using ACDlabs LogP calculator 
http://www.acdlabs.com/resources/freeware/chemsketch/logp. 
	  
1  For selected examples see: a) A. F. Stepan, C. Subramanyam, I. V. 
Efremov, J. K. Dutra, T. J. O’Sullivan, K. J. DiRico, W. S. 
McDonald, A. Won, P. H. Dorff, C. E. Nolan, S. L. Becker, L. R. 
Pustilnik, D. R. Riddell, G. W. Kauffman, B. L. Kormos, L. Zhang, 
Y. Lu, S. H. Capetta, M. E. Green, K. Karki, E. Sibley, K. P. 
Atchison, A. J. Hallgren, C. E. Oborski, A. E. Robshaw, B. Sneed 
and C. J. O’Donnell, J. Med. Chem., 2012, 55, 3414–3424. b) D. B. 
Li, M. Rogers-Evans and E. M. Carreira, Org. Lett., 2011, 13, 6134–
6136. c) J. A. Burkhard, C. Guérot, H. Knust and E. M. Carreira, 
Org. Lett., 2012, 14, 66–69. d) J. A. Burkhard, B. Wagner, H. 
Fischer, F. Schuler, K. Müller and E. M. Carreira, Angew. Chem. Int. 
Ed., 2010, 49, 3524–3527. e) J. Wlochal, R. D. M. Davies and J. 
Burton, Org. Lett., 2014, 16, 4094–4097. f) D. Barnes-Seeman, M. 
Jain, L. Bell, S. Ferreira, S. Cohen, X. Chen, J. Amin, B. Snodgrass 
and P. Hatsis, ACS Med. Chem. Lett., 2013, 4, 514–516. 
2  F. W. Goldberg, J. G. Kettle, T. Kogej, M. W. D. Perry and N. P. 
Tomkinson, Drug Discov. Today, 2015, 20, 11-17. 
3  a) M. Baker, Nat. Rev. Drug Discovery, 2013, 12, 5–7. b) C. W. 
Murray, M. L. Verdonk and D. C. Rees, Trends Pharmacol. Sci., 
2012, 33, 224–232. c) D. E. Scott, A. G. Coyne, S. A Hudson and C. 
Abell, Biochemistry, 2012, 51, 4990–5003. 
4  R. J. Hall, P. N. Mortenson and C. W. Murray, Prog. Biophys. Mol. 
Biol., 2014, 116, 82–91. 
5  A. R. Leach and M. M. Hann, Curr. Opin. Chem. Biol., 2011, 15, 
489–496. 
6  M. M. Hann, Med. Chem. Commun., 2011, 2, 349–355. 
7  A. Nadin, C. Hattotuwagama and I. Churcher, Angew. Chem. Int. Ed., 
2012, 51, 1114–1122. 
8  M. Congreve, R. Carr, C. Murray and H. Jhoti, Drug Discov. Today, 
2003, 8, 876–877. 
9  H. Köster, T. Craan, S. Brass, C. Herhaus, M. Zentgraf, L. Neumann, 
A. Heine and G. Klebe, J. Med. Chem., 2011, 54, 7784–7796. 
10 A. D. Morley, A. Pugliese, K. Birchall, J. Bower, P. Brennan, N. 
Brown, T. Chapman, M. Drysdale, I. H. Gilbert, S. Hoelder, A. 
Jordan, S. V. Ley, A. Merritt, D. Miller, M. E. Swarbrick and P. G. 
Wyatt, Drug Discov. Today, 2013, 18, 1221–1227. 
11  F. Lovering, J. Bikker and C. Humblet, J. Med. Chem., 2009, 52, 
6752–6756. 
12 a) T. J. Ritchie, S. J. F. Macdonald, R. J. Young and S. D. Pickett, 
Drug Discov. Today, 2011, 16, 164–171. b) T. J. Ritchie, S. J. F. 
Macdonald, S. Peace, S. D. Pickett and C. N. Luscombe, Med. Chem. 
Commun., 2013, 4, 673–680. 
13 a) J. Bower and A. Pannifer, Curr. Pharm. Des., 2012, 18, 4685–
4696. b) D. E. Scott, M. T. Ehebauer, T. Pukala, M. Marsh, T. L. 
Blundell, A. R. Venkitaraman, C. Abell and M. Hyvönen, Chem. Bio. 
Chem., 2013, 14, 332–342. 
14 K. F. Morgan, I. A. Hollingsworth and J. A. Bull, Chem. Commun., 
2014, 50, 5203–5205. 
15 a) O. A. Davis and J. A. Bull, Angew. Chem. Int. Ed., 2014, 53, 
14230-14234. b) O. A. Davis and J. A. Bull, Synlett, 2015, DOI: 
10.1055/s-0034-1380412. 
16  For examples, see: a) H. Shimada, S. Hasegawa, T. Harada, T. 
Tomisawa, A. Fujii and T. Takita, J. Antibiot., 1986, 39, 1623–1625. 
	  
O
H
S
O
O
Dihedral angle = 60 degrees
Journal	  Name	   ARTICLE	  
This	  journal	  is	  ©	  The	  Royal	  Society	  of	  Chemistry	  2012	   J.	  Name.,	  2015,	  00,	  1-­‐7	  |	  7 	  
	  
b) M. C. Wani, H. L. Taylor, M. E. Wall, P. Coggon and A. T. 
McPhall, J. Am. Chem. Soc., 1971, 93, 2325–2327. c) C. Li, D. Lee, 
T. N. Graf, S. S. Phifer, Y. Nakanishi, J. P. Burgess, S. Riswan, F. M. 
Setyowati, A. M. Saribi, D. D. Soejarto, N. R. Farnsworth, J. O. F. 
Iii, D. J. Kroll, A. D. Kinghorn, M. C. Wani and N. H. Oberlies, Org. 
Lett., 2005, 7, 5709–5712. 
17  G. Wuitschik, M. Rogers-Evans, K. Müller, H. Fischer, B. Wagner, 
F. Schuler, L. Polonchuk and E. M. Carreira, Angew. Chem. Int. Ed., 
2006, 45, 7736–7739. 
18  a) G. Wuitschik, E. M. Carreira, B. Wagner, H. Fischer, I. Parrilla, F. 
Schuler, M. Rogers-Evans and K. Müller, J. Med. Chem., 2010, 53, 
3227–3246. b) J. A. Burkhard, G. Wuitschik, J.-M. Plancher, M. 
Rogers-Evans and E. M. Carreira, Org. Lett., 2013, 15, 4312–4315. 
19 a) N. H. Powell, J. G. Clarkson, R. Notman, P. Raubo, N. G. Martin 
and M. Shipman, Chem. Commun., 2014, 50, 8797–8800. b) M. 
McLaughlin, R. Yazaki, T. C. Fessard and E. M. Carreira, Org. Lett., 
2014, 16, 4070–4073. 
20  a) E. M. Carreira and T. C. Fessard, Chem. Rev., 2014, 114, 8257–
8322. b) G. Wuitschik, M. Rogers-Evans, A. Buckl, M. Bernasconi, 
M. Märki, T. Godel, H. Fischer, B. Wagner, I. Parrilla, F. Schuler, J. 
Schneider, A. Alker, W. B. Schweizer, K. Müller and E. M. Carreira, 
Angew. Chem. Int. Ed., 2008, 47, 4512–4515. 
21  a) A. F. Stepan, K. Karki, W. S. McDonald, P. H. Dorff, J. K. Dutra, 
K. J. Dirico, A. Won, C. Subramanyam, I. V. Efremov, C. J. 
O’Donnell, C. E. Nolan, S. L. Becker, L. R. Pustilnik, B. Sneed, H. 
Sun, Y. Lu, A. E. Robshaw, D. Riddell, T. J. O’Sullivan, E. Sibley, S. 
Capetta, K. Atchison, A. J. Hallgren, E. Miller, A. Wood and R. S. 
Obach, J. Med. Chem., 2011, 54, 7772–7783. b) A. F. Stepan, G. W. 
Kauffman, C. E. Keefer, P. R. Verhoest and M. Edwards, J. Med. 
Chem., 2013, 56, 6985–6990. c) A. A. Estrada, B. K. Chan, C. Baker-
Glenn, A. Beresford, D. J. Burdick, M. Chambers, H. Chen, S. L. 
Dominguez, J. Dotson, J. Drummond, M. Flagella, R. Fuji, A. Gill, J. 
Halladay, S. F. Harris, T. P. Heffron, T. Kleinheinz, D. W. Lee, C. E. 
Le Pichon, X. Liu, J. P. Lyssikatos, A. D. Medhurst, J. G. Moffat, K. 
Nash, K. Scearce-Levie, Z. Sheng, D. G. Shore, S. Wong, S. Zhang, 
X. Zhang, H. Zhu and Z. K. Sweeney, J. Med. Chem., 2014, 57, 921–
936. 
22  E. M. Skoda, J. R. Sacher, M. Z. Kazancioglu, J. Saha and P. Wipf, 
ACS Med. Chem. Lett., 2014, 5, 900–904. 
23  For a recent report of 3-sulfonyloxetanes see: A.-C. M. A. Nassoy, P. 
Raubo and J. P. A. Harrity, Chem. Commun., 2015, 51, 5914–5916. 
24  For Williamson etherification, see: a) T. Aftab, C. Carter, M. 
Christlieb, J. Hart and A. Nelson, J. Chem. Soc., Perkin Trans. 1, 
2000, 711–722. b) S. F. Jenkinson and G. W. J. Fleet, Chimia, 2011, 
65, 71–75. For cyclisation by epoxide opening ring closure, see: c) T. 
Sone, G. Lu, S. Matsunaga and M. Shibasaki, Angew. Chem. Int. Ed. 
2009, 48, 1677–1680. d) E. D. Butova, A. V. Barabash, A. A. 
Petrova, C. M. Kleiner, P. R. Schreiner and A. A. Fokin, J. Org. 
Chem. 2010, 75, 6229–6235. e) K. Okuma, Y. Tanaka, S. Kaji and H. 
Ohta, J. Org. Chem., 1983, 48, 5133–5134. For halo-cyclisation see: 
f) R. D. Evans, J. W. Magee and J. H. Schauble, Synthesis, 1988, 11, 
862–868. 
	  
	  
25  For Paterno-Büchi reaction, see for example: a) M. Abe, J. Chin. 
Chem. Soc., 2008, 55, 479–486. b) F. Vogt, K. Jödicke, J. Schröder 
and T. Bach, Synthesis, 2009, 24, 4268–4273. 
26  For cyclisation by intramolecular epoxide opening of glycidyl ethers, 
see: a) A. Mordini, S. Bindi, A. Capperucci, D. Nistri, G. Reginato 
and M. Valacchi, J. Org. Chem., 2001, 66, 3201–3205. b) A. 
Mordini, M. Valacchi, C. Nardi, S. Bindi, G. Poli and G. Reginato, J. 
Org. Chem., 1997, 62, 8557–8559. 
27  P. Theobald and W. Okamura, J. Org. Chem., 1990, 55, 741–750. 
28  M. E. Lebrun, P. L. Marquand and C. Berthelette, J. Org. Chem., 
2006, 71, 2009–2013. 
29  Assessment of the suitability of different stationary phases indicated 
that basic alumina activity IV was most appropriate. See: T. 
Boultwood, D. P. Affron, A. D. Trowbridge and J. A. Bull, J. Org. 
Chem., 2013, 78, 6632–6647. 
30  T. E. Barder, S. D. Walker, J. R. Martinelli and S. L. Buchwald, J. 
Am. Chem. Soc., 2005, 127, 4685–4696. 
31  An Fe(OAc)3 catalysed cross-coupling with Grignard reagents was 
also successful with sulfonyl oxetane 1c under Fürstner’s conditions 
to install alkyl groups. See reference 14 for further details, and: A. 
Fürstner and A. Leitner, Angew. Chem. Int. Ed., 2002, 41, 609–612. 
32  P. A. MacFaul, L. Ruston and J. M. Wood, Med. Chem. Commun., 
2011, 2, 140-142. 
33  Gaussian 09, Revision C.01, M. J. Frisch, G. W. Trucks, H. B. 
Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, 
V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, 
X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. 
Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, 
M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. 
A. Montgomery, J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. 
Brothers, K. N. Kudin, V. N. Staroverov, R. Kobayashi, J. Normand, 
K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, 
M. Cossi, N. Rega, M. J. Millam, M. Klene, J. E. Knox, J. B. Cross, 
V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. 
Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. 
Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. 
J. Dannenberg, S. Dapprich, A. D. Daniels, Ö. Farkas, J. B. 
Foresman, J. V. Ortiz, J. Cioslowski and D. J. Fox, Gaussian, Inc., 
Wallingford CT, 2009.  
34  See supporting information for further details.  
